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Background: Liposomes can be modified with different ligands to control their biological 
properties, such as longevity, targeting ability, and intracellular penetration, in a desired fashion. 
The aim of this study was to modify liposomes with a novel mannosylated polyethylene glycol-
phosphatidylethanolamine (M-PEG-PE) ligand to achieve active targeted gene delivery.
Methods: Rat Kupffer cells were isolated and used as model cells for in vitro evaluation of 
cytotoxicity and transfection efficiency. The modified liposomes were intravenously injected 
into the rats, and Kupffer cells were isolated and analyzed by flow cytometry for in vivo gene 
delivery and expression.
Results: The M-PEG-PE-modified liposome-enhanced green fluorescence protein plasmid 
(M-PEG-PE-Lipo-pEGFP) complexes had a particle size of 237 nm and a loading efficiency 
of 90%. The M-PEG-PE-Lipo-pEGFP complexes displayed remarkably higher transfection 
efficiency than unmodified Lipo-pEGFP, both in vitro (51%–30%) and in vivo (43%–27%).
Conclusion: M-PEG-PE could function as an excellent active targeting ligand, and M-PEG-PE-
modified liposomes could be promising active targeted drug delivery vectors.
Keywords: gene delivery, active targeting, mannosylated, polyethylene glycol, phosphatidyle-
thanolamine, liposomes
Introduction
Gene delivery using nonviral pharmaceutical vectors has long been considered, 
because these vectors are less toxic, less immunogenic, and easily modified.1–3 Nonviral 
carriers, such as polymeric nanoparticles,4 liposomes,5 micelles,6 nanocapsules,7 
solid lipid nanoparticles,8 niosomes,9 and other vectors have been widely used as 
gene delivery systems. It has been shown that liposomes can act as biocompatible, 
biodegradable, and nonimmunogenic drug/gene carriers, and the advantages of 
liposomal-encapsulated drugs/genes are a prolonged duration of exposure, selective 
delivery to the intended site of action, and improved therapeutic index.10,11 Among the 
liposomes, the   Lipofectamine™ 2000 transfection reagent is a proprietary formulation 
for transfection of nucleic acids (DNA and RNA) into cells, and has been widely used 
by many researchers.12–14
Liposomes can be modified with different kinds of ligands to control their biological 
properties such as longevity, targeting ability, and intracellular penetration, in a desired 
fashion.15 Modification of liposomes using polyethylene glycol (PEG) has emerged as 
a common strategy to ensure stealth shielding and long circulation of liposomal drug/
gene delivery systems. PEG modification could also provide liposomes with active 
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targeting properties by enabling covalent attachment of a 
wide assortment of targeting ligands by amide bonding or 
disulfide bridge formation.16
A series of PEG-containing ligands, commonly known as 
PEG-phosphatidylethanolamine (PEG-PE) conjugates, was 
described by Torchilin et al who demonstrated that PEG-PE 
conjugates with various PEG lengths and terminal-targeted 
moieties can provide extremely stable, long-circulating, and 
actively targeted nanocarriers which spontaneously accumulate 
at specific sites.4,6,17 PEG-PE was subsequently used widely in 
liposomal formulations,18,19 and more recently, several such 
ligands (eg, PEG-PE and TAT-PEG-PE) have also been used 
for targeted delivery of drugs/genes.20–22
Saccharide ligands, such as galactose, mannose, lactose, 
and maltose, have been extensively investigated for modifi-
cation of liposomes to achieve site-specific targeting.23,24 In 
this study, a novel conjugated ligand, ie, mannose-PEG-PE 
(M-PEG-PE), was synthesized, and M-PEG-PE-modified 
Lipofectamine™ 2000 (Lipo) liposomes were investigated 
as an active targeting gene delivery system. Enhanced green 
fluorescence protein plasmid (pEGFP) was used as the model 
gene. The novel modified vectors were delivered intrave-
nously into rats and the in vivo targeting behavior of M-PEG-
PE-modified liposome-pEGFP (M-PEG-PE-Lipo-pEGFP) 
complexes was investigated in liver macrophages and com-
pared with that of unmodified Lipo-pEGFP complexes.
Materials and methods
Materials
Butyl carbonyl (Boc)-NH-PEG2000-COOH was purchased 
from Shanghai Yarebio Co Ltd (Shanghai, China). 
Mannose, L-α-phosphatidylethanolamine (PE), MTT 
(3-[4,5-dimethyl-2- thiazolyl]-2,5-diphenyl-2H-  tetrazolium 
bromide), and concanavalin A were purchased from 
  Sigma-Aldrich Co, Ltd, (St, Louis, MO). pEGFP-N1 was 
provided by Shandong University (Shandong, China). 
Quant-iT™ PicoGreen® dsDNA quantitation reagent and 
Lipofectamine 2000 were obtained from Invitrogen Life 
Technologies (Carlsbad, CA). All other chemicals were of 
analytical grade or higher.
Animals
Adult male Sprague-Dawley rats (10–11 weeks old) were 
  purchased from the Medical Animal Testing Center of 
Shandong Province and housed under standard laboratory 
conditions. All animal experiments complied with the 
requirements of the National Act on the Use of Experimental 
Animals (People’s Republic of China).
Synthesis of M-PEG-PE ligands
M-PEG-PE ligands were synthesized as described in 
Figure 1. Boc-NH-PEG-COOH 100 mg was dissolved in 
dimethyl sulfoxide and stirred with 36 mg of PE to form a 
mixture. 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide 
(EDC⋅HCl) 72 mg) and triethylamine (1 equivalent of 
EDC⋅HCl) were dissolved in dimethyl sulfoxide and added 
dropwise into the mixture in an ice bath, stirred for 36 hours, 
and concentrated hydrochloric acid was then used to detach 
the Boc group and produce NH2-PEG-CO-NH-PE. Man-
nose 50 mg was dissolved with 1 M sodium hydroxide of 
1 mL and stirred for 30 minutes for alkalinization, then 
1 mL of   chloroacetic acid (20%) was added to the solution 
and stirred in an oil bath at 60°C for 6 hours. Following 
this, hydrochloric acid 1 M was added until pH was 2–3 
to complete the carboxymethylation of mannose.8 Car-
boxymethylated mannose was then stirred with NH2-PEG-
CO-NH-PE in dimethyl sulfoxide solution, and EDC⋅HCl 
mixed with triethylamine (one equivalent of EDC⋅HCl in 
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Figure 1 General reaction scheme for synthesis of the mannosylated polyethylene glycol-phosphatidylethanolamine ligand. 
Abbreviations: Boc, butyl carbonyl; PE, phosphatidylethanolamine; PEG, polyethylene glycol; DMSO, dimethyl sulfoxide; TEA, triethylamine.
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dimethyl sulfoxide) was added dropwise into the solution in 
an ice bath and stirred for 24 hours. Dimethyl sulfoxide was 
moved by rotary evaporation, and the product was dialyzed 
against Milli-Q (Billerica, MA) water for 24 hours to form 
M-PEG-PE.
Fabrication of Lipo-pEGFP complexes
Lipo-pEGFP complexes were prepared according to the 
manufacturer’s instructions for Lipofectamine 2000. Briefly, 
100 µL of pEGFP 1 µg/µL was mixed with 200 µL of 
  Lipofectamine 2000 by vortexing for 30 seconds. Incubation 
of the mixture for 30 minutes at room temperature-facilitated 
formation of the DNA-loaded liposomes (Figure 2).
Modification of Lipo-pEGFP  
with M-PEG-PE
M-PEG-PE-Lipo-pEGFP complexes were produced by the 
solvent diffusion method (Figure 2).24,25 Briefly, M-PEG-PE 
ligands were dissolved in 2 mL of phosphate-buffered saline 
(pH 7.4). The solution was then added dropwise into 10 mL 
of Lipo-pEGFP complexes and stirred at 600 rpm and 
room temperature, with immediate surface modification. 
  Subsequently, free M-PEG-PE was removed from the modi-
fied Lipo-pEGFP by gel chromatography using a Sephadex® 
G-50 column (GE Healthcare, Uppsala, Sweden). The com-
plexes obtained were resuspended in Milli-Q water, washed 
three times, and filtered through a membrane with a 0.80 µm 
pore size to obtain M-PEG-PE-Lipo-pEGFP. To optimize 
the modification ratio, M-PEG-PE ligands dissolved in 
phosphate-buffered saline were designed at different weight 
ratios for the Lipo-pEGFP (w/w). The particle size and zeta 
potential of the complexes were determined using a Zetasizer 
Nano ZS (Malvern Instruments, Worcestershire, UK). The 
shape of the M-PEG-PE-Lipo-pEGFP was examined by 
transmission electron microscopy. Samples were prepared 
by placing one drop of suspension onto a copper grid and 
dried, followed by negative staining with one drop of a 3% 
aqueous solution of sodium phosphotungstate for contrast 
enhancement. The air-dried samples were then examined 
directly under the transmission electron microscope.
M-PEG-PE modification  
and pEGFP-loading capacity  
of M-PEG-PE-Lipo-pEGFP
To confirm the success of modification and determine 
the optimum ratio of M-PEG-PE to Lipo-pEGFP, several 
experiments were carried out as follows.
PicoGreen fluorometry assay
During the modification procedure, M-PEG-PE ligands were 
coated onto Lipo-pEGFP carriers due to the electric charge and 
lipophilic interaction. A PicoGreen fluorometry assay was used 
to determine the appropriate modification rate of M-PEG-PE 
ligands and also to quantitate the amount of pEGFP carried 
by the optimally modified liposomes.26 Different ratios of 
M-PEG-PE to Lipo-pEGFP (from 2% to 30%, w/w) were used 
to prepare the M-PEG-PE-Lipo-pEGFP complexes, and the 
pEGFP was isolated from M-PEG-PE-Lipo-pEGFP by cen-
trifugation at 1000 g and 4°C for 30 minutes. The concentration 
of pEGFP was determined by fluorescence and comparing the 
sample with the blank liposome supernatant. The amount of 
pEGFP loaded into the liposomes was calculated according 
to the linear calibration curve of pEGFP:
Gene loading quantity (%) =   (Total of pEGFP 
– free pEGFP)/total DNA  
× 100.
Concanavalin A agglutination study
A concanavalin A agglutination assay was performed to 
confirm that the M-PEG-PE ligands were successfully modi-
fied onto the Lipo-pEGFP surface. Binding of the terminal 
M-PEG-PE M-PEG-PE-Lipo/pEGFP Lipo/pEGFP Liposomes pEGFP
Figure 2 Preparation and modification of liposome-pEGFP complexes. 
Abbreviations: M-PEG-PE, mannosylated polyethylene glycol-phosphatidylethanolamine; Lipo, Lipofectamine 2000; pEGFP, green fluorescence protein plasmid.
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α-mannose residues to concanavalin A causes agglutination 
of the complexes in solution, resulting in an increase in tur-
bidity.27–29 Therefore, 100 µL of M-PEG-PE-Lipo-pEGFP 
complexes was added into 500 µL of concanavalin A 1 mg/mL 
in phosphate-buffered saline (pH 7.4) with 5 mM of calcium 
chloride (CaCl2) and 5 mM of magnesium chloride (MgCl2) at 
room temperature. The increase in turbidity at 360 nm (OD360) 
was monitored at room temperature for 3 minutes.
Isolation and culture of Kupffer cells
Kupffer cells were isolated from Sprague-Dawley rats under 
pentobarbitone anesthesia using a method described else-
where.30–32 In brief, the rat portal vein was cannulated and 
perfused with Hank’s buffered salt solution for 10 minutes, the 
liver was excised, and the perfusate was discarded. The liver 
was then perfused with 0.2% pronase, then with a recirculat-
ing solution of 0.05% pronase and 0.05% collagenase until 
the liver was digested. The liver was thereafter cut into small 
pieces, suspended in a solution containing 0.02% pronase, 
0.05% collagenase, and 0.005% DNase, and then agitated. 
Following digestion, the liver homogenate was filtered through 
sterile gauze and centrifuged at 1000 g and 4°C for 10 minutes. 
The supernatant was removed and the pellet then resuspended 
in Percoll™ gradient. Aliquots of this cell suspension were 
added to aliquots of Percoll gradient. These were carefully 
overlaid with Hank’s balanced salt solution and centrifuged. The 
nonparenchymal cell-enriched layer observed at the interface 
between the two layers was carefully harvested and diluted with 
Hank’s balanced salt solution. The suspension was then centri-
fuged to precipitate the Kupffer cells, which were then seeded 
into a 96-well microtiter plate at a density of 2 × 104 cells/well 
in RPMI 1640 supplemented with 10% fetal bovine serum and 
antibiotics. After incubation at 37°C for 2 hours under 5% CO2 
atmosphere, the culture medium was replaced by 200 µL of 
fresh RPMI 1640 to yield the purified Kupffer cells.
The isolated Kupffer cells were defined on the basis of 
phagocytosis of latex beads and positive immunostaining 
with the antibody to the ED2 epitope. Using the abovemen-
tioned method, about 9.35 × 107/rat liver Kupffer cells were 
obtained, the purity of which was about 92.6% (1.01 × 108 
nonparenchymal rat liver cells). The isolated and purified rat 
Kupffer cells retained their in vivo morphological, biological, 
and immunological characteristics.
In vitro cytotoxicity evaluation  
and transfection analysis
The in vitro cytotoxicity of M-PEG-PE-Lipo-pEGFP in 
Kupffer cells was evaluated by MTT assay.30 The Kupffer 
cells were incubated with M-PEG-PE-Lipo-pEGFP and 
unmodified Lipo-pEGFP at various concentrations (10, 20, 
50, 100, and 200 µg/mL) for 48 hours at 37°C and 5% CO2. 
The cell viability was then assessed by MTT assay; 5 mg/mL 
of MTT in phosphate-buffered saline was then added to each 
well and the plate was incubated for an additional 4 hours 
at 37°C and a 5% CO2 atmosphere. The medium containing 
MTT was then removed, and the crystals formed by living 
cells were dissolved in 100 µL of dimethyl sulfoxide. The 
absorbance at 570 nm was determined by microplate reader. 
Untreated cells were taken as a control with 100% viability, 
and cells without the addition of MTT were used as a blank 
to calibrate the spectrophotometer to zero absorbance. The 
relative cell viability (%) compared with control cells was 
calculated as (Abssample/Abscontrol) × 100.
For analysis of transfection efficiency, the Kupffer cells 
were seeded into 24-well plates at a density of 1 × 105 cells/
well in 1 mL of RPMI 1640 with 10% fetal bovine serum. 
After about 24 hours, when the cells were at about 80%–90% 
confluence, the media were replaced with 400 µL of transfec-
tion media containing M-PEG-PE-Lipo-pEGFP. Naked DNA 
was used as a negative control and unmodified Lipo-pEGFP 
was used as a positive control. The original incubation 
medium was replaced with 1 mL of complete medium after 
incubation at 37°C for 4 hours under a 5% CO2 atmosphere. 
The cells were incubated and studied at 72 hours following 
transfection. The fluorescent cells were observed using an 
inverted fluorescence microscope, at which time photographs 
were taken. To quantitate transfection efficiency further, the 
cells were washed with 1 mL of phosphate-buffered saline 
(100 g, 4°C for 5 minutes) and detached with trypsin-EDTA. 
The supernatant was discarded and resuspended in 300 µL 
of phosphate-buffered saline, and the fluorescence intensity 
of the cells was determined using a flow cytometer equipped 
with a 488 nm argon laser for excitation. For each sample, 
about 10,000 events were collected and fluorescence was 
detected. Signals were amplified in logarithmic mode for 
fluorescence to determine the positive events by a standard 
gating technique. The percentage of positive events was 
calculated as the events within the gate divided by the total 
number of events, excluding cell debris.
In vivo gene delivery
Adult male Sprague-Dawley rats were divided into three 
groups (six rats in each group) and injected intravenously 
with 1 mL of M-PEG-PE-Lipo-pEGFP, Lipo-pEGFP, and 
naked pEGFP (300 µL per rat, containing 30 µg of pEGFP). 
At predetermined time intervals, rat Kupffer cells were 
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isolated as described earlier. The Kupffer cells were then 
seeded into 24-well plates, and incubated until 48 hours 
after transfection. The cells were then washed with 1 mL of 
phosphate-buffered saline (100 g and 4°C for 5 minutes) and 
detached with trypsin-EDTA. The supernatant was discarded 
and resuspended in 300 µL of phosphate-buffered saline, 
mixed well, and flow cytometry was performed to deter-
mine the amount of Kupffer cells that had been successfully 
transfected.
Statistical analysis
All studies were repeated three times and measurements 
were carried out in triplicate. Results are reported as the 
mean ± standard deviation. Statistical significance was 
determined using the Student’s t-test. Differences between 
experimental groups were considered significant when the 
P value was ,0.05.
Results
Structural confirmation of M-PEG-PE 
ligands
The structure of M-PEG-PE was confirmed by infrared 
and  1H nuclear magnetic resonance (NMR) spectroscopy. 
  Infrared ν/cm−1: 3521.5 (–NH–, –OH); 1818.3 (–C=O); 
1665.4 (–HN–CO–); 1631.9 (–HN–CO–). 1H NMR (dimethyl 
sulfoxide-d6, 300 mHz) δs 2.45 (CH2CO), 3.28 (CH2 N), and 
6.08 (NH). The production rate was around 65%.
Characterization of DNA-loaded 
liposomes
Transmission electron microscopic images of the vectors 
are shown in Figure 3. The mean particle size, polydis-
persity index, and zeta potential of Lipofectamine 2000, 
  Lipo-pEGFP, and M-PEG-PE-Lipo-pEGFP are characterized 
and summarized in Table 1.
Optimization of M-PEG-PE modification 
rate
The quantity of pEGFP loaded into the variously modified 
liposomes was calculated and is displayed in Figure 4. 
Unmodified liposomes (0%) reached a gene loading quantity 
of 90%. With the increasing modification rate (from 2% 
to 10%), the pEGFP loading amount showed no obvious 
change (all around 90%). When the ratio of the ligands was 
above 10%, the loading capacity decreased, and only 15% 
gene carrying was observed at the ratio of 30%. The optimum 
rate was 10%, and this ratio was used for the investigations 
described below.
Determination of M-PEG-PE modification
A concanavalin A agglutination study was used to identify 
further that the M-PEG-PE ligands were successfully modi-
fied onto the Lipo-pEGFP surface. As shown in Figure 5, the 
turbidity of M-PEG-PE-Lipo-pEGFP appeared to increase, 
while the Lipofectamine 2000 and Lipo-pEGFP formulations 
appeared not to show any significant increase in turbidity.
In vitro cytotoxicity evaluation
The in vitro cytotoxicity of M-PEG-PE-Lipo-pEGFP and 
unmodified Lipo-pEGFP at various concentrations was 
evaluated by MTT assay. The cell viability of the liposomes 
AB
C
100 nm 100 nm
100 nm
Figure 3 Transmission electron microscopic images of Lipofectamine-green fluorescence 
protein  plasmid  (A),  mannosylated  polyethylene  glycol-phosphatidylethanolamine-
Lipofectamine-green fluorescence protein plasmid (B and C).
Table 1 Particle size and zeta potential of liposomes (mean ± standard deviation, n = 3)
Sample properties Lipofectamine™ Lipo-pEGFP M-PEG-PE- Lipo/pEGFP
Mean particle size (nm) 128.5 ± 2.9 205.9 ± 9.6 237.2 ± 10.1
Polydispersity index   0.09 ± 0.01   0.16 ± 0.03   0.18 ± 0.07
Zeta potential (mV) 39.56 ± 2.85 26.21 ± 1.69 18.92 ± 1.18
Abbreviations: Lipo, Lipofectamine™; pEGFP, green fluorescence protein plasmid; M-PEG-PE, mannosylated polyethylene glycol-phosphatidylethanolamine.
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over the studied concentration range (10–200 µg/mL) 
was between 80% and 100% compared with the controls 
(Figure 6). M-PEG-PE-Lipo-pEGFP showed no greater cyto-
toxicity than Lipo-pEGFP at any concentration (P . 0.05).
In vitro transfection analysis
The in vitro transfection efficiency of M-PEG-PE-Lipo-
pEGFP and Lipo-pEGFP in Kupffer cells was analyzed after 
72 hours of transfection. Naked DNA was used as a negative 
control. As shown in the fluorescent images in Figure 7, when 
compared with naked DNA and Lipo-pEGFP, M-PEG-PE-
Lipo-pEGFP showed higher transfection efficiency at the 
different time intervals. The cells exhibited highest efficiency 
at 48 hours. Flow cytometry results showed that the highest 
in vitro efficiency of M-PEG-PE-Lipo-pEGFP at 48 hours 
was over 50%. Compared with around 30% efficiency for 
Lipo-pEGFP, the advantage of the modified vectors was 
significant.
In vivo gene delivery
After intravenous injection of 1 mL of M-PEG-PE-Lipo-
pEGFP, Lipo-pEGFP, and naked pEGFP, the rats were 
euthanized and the Kupffer cells were isolated at 48 hours. 
Flow cytometry was applied to quantitate the amount of 
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Figure 4 Optimization of the M-PEG-PE modification rate. 
Abbreviations: M-PEG-PE, mannosylated polyethylene glycol-phosphatidylethanolamine; Lipo, Lipofectamine™; pEGFP, green fluorescence protein plasmid.
0
0.02
0.04
0.06
0.08
0.1
0.12
0.14
0.16
0.18
03 06 09 0 120 150 180 210
T (s)
O
D
3
6
0 Lipofectamine™ 2000
Lipo/pEGFP
M-PEG-PE-Lipo/pEGFP
Figure 5 Turbidity of Lipofectamine™ 2000, Lipo-pEGFP, and M-PEG-PE-Lipo-pEGFP at different time intervals. 
Abbreviations: M-PEG-PE, mannosylated polyethylene glycol-phosphatidylethanolamine; Lipo, Lipofectamine™; pEGFP, green fluorescence protein plasmid.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1084
Kong et alInternational Journal of Nanomedicine 2012:7
cells that had been successfully transfected. As shown in 
Figure 8, M-PEG-PE-Lipo-pEGFP showed a remarkably 
higher transfection efficiency than unmodified Lipo-pEGFP 
(P , 0.05) and naked pEGFP (P , 0.05).
Discussion
Liposome-based delivery systems have long been identified 
as safe and effective drug carriers that are amenable to 
  modification with cell-specific targeting ligands.21 In regards 
to gene delivery, one of the most popular liposomes is 
Lipofectamine 2000 which is a proprietary formulation for 
the transfection of nucleic acids into cells.33 In the present 
study, novel conjugated M-PEG-PE was synthesized and 
M-PEG-PE-modified Lipofectamine 2000 liposomes were 
investigated as a active targeting gene delivery system.
The investigation began with the synthesis of M-PEG-PE, 
in which mannose was the target moiety which could bind 
to the mannose receptor in the macrophage, and PEG-PE 
was the spacer linked into the surface of the liposomes. 
It is known that the method of connection between the 
carbohydrate and carrier surface through a flexible spacer 
influences the targeting ability and cellular uptake of the 
vectors.15 For example, the length and flexibility of the spacer 
between the carbohydrate head group and liposome surface 
mainly influence the target specificity and uptake of liposome 
by macrophages. PEG-PE conjugates have been reported 
and TATp-PEG2000-PE conjugates have been used for the 
modification of liposomes to form active targeting vectors.20 
Therefore, PEG2000-PE was used as the anchor.
It is also known that the saccharide group density is 
an important factor for targeting efficiency.34,35 Generally, 
vectors modified with a higher content of sugar residues 
exhibit more efficient cellular recognition and internalization 
compared with those having a lower sugar density. Therefore, 
theoretically, the more M-PEG-PE ligands modified onto the 
carriers, the better the targeted delivery achieved. However, 
excessive modification could trigger the disintegration of 
liposomes;36 pEGFP could leak out of the vector and cause a 
notable decrease of the gene loading capacity. A PicoGreen 
fluorometry assay was used to determine the appropriate 
modification rate of M-PEG-PE ligands and also to quanti-
tate the amount of pEGFP carried by the optimally modified 
liposomes.
Nonmodified liposomes reached a gene loading quantity 
of 90.34% (Figure 4). With an increase in the modification 
rate, the loading amount of pEGFP showed no obvious 
change until the ratio of the ligands was above 10%. The 
loading capacity was decreased to 10%–30%, indicating 
that the optimal modification rate would be 10% (ligands/
carrier, w/w). Therefore, 10% was finally determined as 
the ligand to carrier ratio and the gene loading amount of 
the modified liposomes was 90%. There was no significant 
difference in loading capacity between the modified and 
unmodified liposomes, indicating that binding of a mannose-
containing ligand onto the liposome surface did not release 
DNA from the complexes.
Concanavalin A was the first legume lectin recognized 
as being mannose-specific, and is believed to play a role in 
recognition of mannose-containing vectors.27,37 It has been 
used extensively for the evaluation of glycoconjugates.38–40 
In our research, a concanavalin A agglutination study 
was used to identify further that the M-PEG-PE ligands 
were successfully modified onto the Lipo-pEGFP surface. 
M-PEG-PE-Lipo-pEGFP showed an apparent increase in 
turbidity (Figure 5), whereas the Lipofectamine 2000 and 
Lipo-pEGFP formulations appeared to show no significant 
increase in turbidity. This could be taken as evidence of the 
success of the mannose-containing ligands modified onto 
the liposome surface.
Macrophages play a major role in the immune response 
to foreign antigens, and targeting macrophages is one of 
the important therapeutic methods used to treat genetic 
metabolic diseases such as Gaucher’s disease and human 
immunodeficiency virus infection.41 Kupffer cells are liver-
specific resident macrophages that play an integral part in 
physiological homeostasis of the liver. They have significant 
roles in acute and chronic responses of the liver to bacterial 
and viral infections, toxic or carcinogenic attack, as well 
as mediating hepatotoxicity.42 In this study, rat Kupffer 
cells were isolated and used as model cells for in vitro 
cytotoxicity evaluation and transfection analysis. The cell 
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viabilities of the liposomes over the studied   concentration 
range were between 80% and 100% compared with controls 
(Figure 6). M-PEG-PE-Lipo-pEGFP showed no greater 
cytotoxicity than Lipo-pEGFP at all concentrations. When 
compared with naked DNA and Lipo-pEGFP, M-PEG-
PE-Lipo-pEGFP had greater transfection efficiency at 
all time points (Figure 7). This may be explained by the 
sugar-lectin-mediated active targeting mechanism. The 
M-PEG-PE-modified pEGFP-loaded liposomes were more 
likely to bind to Kupffer cells via the mannose receptor 
on the cells and deliver DNA more easily into the cells to 
express EGFP.
The gene delivery ability of the modified gene vector 
could be tested further in animal models. In vivo gene deliv-
ery and expression studies were used in rats. After intravenous 
injection, the rats were euthanized and the Kupffer cells were 
isolated at 48 hours and analyzed by flow cytometry. M-PEG-
PE-Lipo-pEGFP displayed remarkably higher transfection 
efficiency (43%) than unmodified Lipo-pEGFP (26%) and 
naked pEGFP (1.5%), as shown in Figure 8. This could 
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Abbreviations: M-PEG-PE, mannosylated polyethylene glycol-phosphatidylethanolamine; Lipo, Lipofectamine™; pEGFP, green fluorescence protein plasmid.
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only be explained by the mannosylated PEG-PE-modified 
liposomes having the ability to target liver Kupffer cells and 
to deliver more genes into cells, displaying higher transfec-
tion efficiency. These observations strongly support the 
active targeting ability of M-PEG-PE-modified liposomes, 
and the resulting vectors would be very useful for in vivo 
gene delivery.
Conclusion
This study showed that mannose-mediated targeting can 
successfully transfer genes into cells expressing the mannose 
receptor. It could also demonstrate that having a targeting 
ligand, such as M-PEG-PE, in liposome formulations can 
significantly improve the transfection efficiency of a lipo-
somal formulation. M-PEG-PE-Lipo-pEGFP had remarkably 
higher transfection efficiency both in vitro and in vivo than 
unmodified Lipo-pEGFP. It could be concluded that man-
nosylated PEG-PE could function as an excellent active tar-
geting ligand, and M-PEG-PE-modified Lipofectamine 2000 
could be a promising active targeting drug delivery vector.
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Supplementary in vivo gene 
delivery data
Details of the experiments and data analysis are as follows. 
Cells were washed in cold phosphate-buffered saline 
three times and the fluorescent intensity of the cells was 
determined using a flow cytometer equipped with a 488 nm 
argon laser for excitation. For each sample, about 10,000 
events were collected and fluorescence was detected. Signals 
were amplified in the logarithmic mode for fluorescence to 
determine the positive events by a standard gating technique. 
The percentage of positive events was calculated as the 
events within the gate divided by the total number of events, 
excluding cell debris.
The pictures of flow cytometry analysis are shown 
in two ways, ie, as in Figure 8 and as a quadrantal rule 
diagram. The percentage of cells transfected with pEGFP 
appear at the upper right and lower right quadrants of 
the diagram. 
The data in the quadrantal rule diagram for the in vivo study are 
as follows
Quad X, mean Y, mean Events % Total % Gated
Figure 8A: UR + LR = 1.75
1  UL 8.8 10.1 3 0.02 69.09
2  UR 146.4 29.5 26 0.21 1.10
3  LL 2.8 2.3 12113 96.34 29.25
4  LR 73.4 4.7 44 0.35 0.65
Figure 8B: UR + LR = 27.91
1  UL 8.8 10.1 3 0.02 49.83
2  UR 146.4 29.5 26 0.21 20.17
3  LL 2.8 2.3 12113 96.34 22.28
4  LR 73.4 4.7 44 0.35 7.74
Figure 8C: UR + LR = 44.20
1  UL 8.8 10.1 3 0.02 38.35
2  UR 146.4 29.5 26 0.21 31.64
3  LL 2.8 2.3 12113 96.34 17.43
4  LR 73.4 4.7 44 0.35 12.56
Data on dose optimization are as follows (gene expression was 
analyzed at 48 hours after intravenous injection)
Quad X, mean Y, mean Events % Total % Gated
Dose: 5 µg of pEGFP per rat gene expression: 2.59
1  UL 8.8 10.1 3 0.02 66.01
2  UR 146.4 29.5 26 0.21 2.24
3  LL 2.8 2.3 12113 96.34 31.40
4  LR 73.4 4.7 44 0.35 0.35
Dose: 10 µg of pEGFP pre rat gene expression: 4.92
1  UL 8.8 10.1 3 0.02 67.06
2  UR 146.4 29.5 26 0.21 3.10
3  LL 2.8 2.3 12113 96.34 28.37
4  LR 73.4 4.7 44 0.35 1.82
Dose: 15 µg of pEGFP per rat gene expression: 16.96
1  UL 8.8 10.1 3 0.02 59.12
2  UR 146.4 29.5 26 0.21 10.31
3  LL 2.8 2.3 12113 96.34 23.08
4  LR 73.4 4.7 44 0.35 6.65
Dose: 20 µg of pEGFP per rat gene expression: 26.38
1  UL 8.8 10.1 3 0.02 53.53
2  UR 146.4 29.5 26 0.21 16.40
3  LL 2.8 2.3 12113 96.34 20.37
4  LR 73.4 4.7 44 0.35 9.98
Dose: 25 µg of pEGFP per rat gene expression: 32.96
1  UL 8.8 10.1 3 0.02 46.92
2  UR 146.4 29.5 26 0.21 23.07
3  LL 2.8 2.3 12113 96.34 21.10
4  LR 73.4 4.7 44 0.35 9.89
Dose: 30 µg of pEGFP per rat gene expression: 44.20
1  UL 8.8 10.1 3 0.02 38.35
2  UR 146.4 29.5 26 0.21 31.64
3  LL 2.8 2.3 12113 96.34 17.43
4  LR 73.4 4.7 44 0.35 12.56
Dose: 40 µg of pEGFP per rat gene expression: 39.91
1  UL 8.8 10.1 3 0.02 39.83
2  UR 146.4 29.5 26 0.21 30.17
3  LL 2.8 2.3 12113 96.34 20.28
4  LR 73.4 4.7 44 0.35 9.74
Dose: 50 µg of pEGFP per rat gene expression: 44.38
1  UL 8.8 10.1 3 0.02 39.88
2  UR 146.4 29.5 26 0.21 30.12
3  LL 2.8 2.3 12113 96.34 16.72
4  LR 73.4 4.7 44 0.35 14.26
Dose: 60 µg of pEGFP per rat gene expression: 40.91
1  UL 8.8 10.1 3 0.02 40.15
2  UR 146.4 29.5 26 0.21 32.33
3  LL 2.8 2.3 12113 96.34 19.14
4  LR 73.4 4.7 44 0.35 8.58
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